{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:28:03Z","timestamp":1790213283707,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2004,1]]},"DOI":"10.2515\/therapie:2004021","type":"journal-article","created":{"date-parts":[[2007,3,14]],"date-time":"2007-03-14T15:42:11Z","timestamp":1173886931000},"page":"105-112","source":"Crossref","is-referenced-by-count":34,"title":["Les syndromes parkinsoniens m\u00e9dicamenteux"],"prefix":"10.1016","volume":"59","author":[{"given":"Nhan","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Pradel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00eblle","family":"Micallef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Blin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.2515\/therapie:2004021_bb2105","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinico-pathologic study of 100 cases","volume":"55","author":"Hugues","year":"1992","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.2515\/therapie:2004021_bb2110","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/00005072-199603000-00001","article-title":"Neuropathology of Parkinson\u2019s disease","volume":"55","author":"Forno","year":"1996","journal-title":"J Neuropathol Exp Neurol"},{"issue":"5","key":"10.2515\/therapie:2004021_bb2115","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJM198308043090511","article-title":"Parkinson\u2019s disease in a chemist working with 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine (MPTP) [letter]","volume":"309","author":"Langston","year":"1983","journal-title":"N Engl J Med"},{"key":"10.2515\/therapie:2004021_bb2120","first-page":"246","volume":"1","author":"Rascol","year":"1998"},{"key":"10.2515\/therapie:2004021_bb2125","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1126\/science.1074501","article-title":"Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA (\u2018ecstasy\u2019)","volume":"297","author":"Ricaurte","year":"2002","journal-title":"Science"},{"key":"10.2515\/therapie:2004021_bb2130","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1126\/science.301.5639.1479b","article-title":"Retraction","volume":"301","author":"Ricaurte","year":"2003","journal-title":"Science"},{"issue":"6","key":"10.2515\/therapie:2004021_bb2135","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S0161-813X(01)00046-8","article-title":"Is methamphetamine abuse a risk factor in parkinsonism?","volume":"22","author":"Guilarte","year":"2001","journal-title":"Neurotoxicology"},{"key":"10.2515\/therapie:2004021_bb2140","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1472-8206.1994.tb00808.x","article-title":"Drug-induced parkinsonism: a review","volume":"8","author":"Montastruc","year":"1994","journal-title":"Fundam Clin Pharmacol"},{"key":"10.2515\/therapie:2004021_bb2145","first-page":"1109","article-title":"Mouvements anormaux d\u2019origine m\u00e9dicamenteuse","volume":"47","author":"Montastruc","year":"1997","journal-title":"Rev Prat"},{"key":"10.2515\/therapie:2004021_bb2150","series-title":"19\u00e8me journ\u00e9es de pharmacovigilance","article-title":"Adverse drug reaction in hospitalized patients with psychiatric disorders: detection and cost analysis [poster]","author":"Tazaroute","year":"1998"},{"key":"10.2515\/therapie:2004021_bb2155","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1136\/jnnp.62.1.10","article-title":"Prevalence of parkinsonism and Parkinson\u2019s disease in Europe: the Europarkinson Collaborative Study","volume":"62","author":"De Rijk","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.2515\/therapie:2004021_bb2160","first-page":"757","article-title":"Syndromes parkinsoniens d\u2019origine m\u00e9dicamenteuse: exp\u00e9rience d\u2019un centre r\u00e9gional de pharmacovigilance sur dix ans","volume":"150","author":"Llau","year":"1994","journal-title":"Rev Neurol"},{"key":"10.2515\/therapie:2004021_bb2165","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/1353-8020(96)00013-2","article-title":"Drug-induced parkinsonism in a movement disorders unit: a four-year survey","volume":"2","author":"Jimenez-Jimenez","year":"1996","journal-title":"Parkinsonism Relat Disord"},{"key":"10.2515\/therapie:2004021_bb2170","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1212\/WNL.37.5.881","article-title":"Flunarizine and cinnarizine-induced extrapyramidal reactions","volume":"7","author":"Micheli","year":"1987","journal-title":"Neurology"},{"key":"10.2515\/therapie:2004021_bb2175","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/mds.870040205","article-title":"Movement disorder and depression due to flunarizine and cinnarizine","volume":"4","author":"Micheli","year":"1989","journal-title":"Mov Disord"},{"key":"10.2515\/therapie:2004021_bb2180","first-page":"1117","article-title":"Mouvements anormaux. Pour la pratique","volume":"47","author":"Damier","year":"1997","journal-title":"Rev Prat"},{"key":"10.2515\/therapie:2004021_bb2185","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0987-7053(01)00273-8","article-title":"Contributions of PET and SPECT to the understanding of the physiopathology of Parkinson\u2019s disease","volume":"31","author":"Thobois","year":"2001","journal-title":"Neurophysiol Clin"},{"issue":"3","key":"10.2515\/therapie:2004021_bb2190","doi-asserted-by":"crossref","first-page":"180","DOI":"10.2165\/00002018-199716030-00004","article-title":"Drug-induced movement disorders","volume":"16","author":"Jimenez-Jimenez","year":"1997","journal-title":"Drug Saf"},{"key":"10.2515\/therapie:2004021_bb2195","series-title":"Neuropharmacologie clinique, le m\u00e9dicament en neurologie","first-page":"1","article-title":"Histoire de la neuropharmacologie","author":"Duch\u00eane-Marullaz","year":"1989"},{"key":"10.2515\/therapie:2004021_bb2200","series-title":"Psychotropic drugs","first-page":"485","author":"Delay","year":"1957"},{"key":"10.2515\/therapie:2004021_bb2205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0014-2999(02)02496-2","article-title":"Can antipsychotic drugs be classified by their effects on a particular group of dopamine neurons in the brain?","volume":"455","author":"Westerink","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"10.2515\/therapie:2004021_bb2210","first-page":"538","article-title":"Positron emission tomographic analysis of central D2 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine","volume":"9","author":"Farde","year":"1992","journal-title":"J Clin Psychiatry"},{"issue":"Suppl. B","key":"10.2515\/therapie:2004021_bb2215","first-page":"67-B69","article-title":"D1-, D2-, and 5\u2013HT2-receptor occupancy in clozapine-treated patients","volume":"55","author":"Farde","year":"1994","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"10.2515\/therapie:2004021_bb2220","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S0893-133X(96)00100-5","article-title":"The D2 receptor occupancy profile of loxapine determined using PET","volume":"15","author":"Kapur","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.2515\/therapie:2004021_bb2225","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0920-9964(00)00009-8","article-title":"Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial","volume":"46","author":"Heck","year":"2000","journal-title":"Schizophr Res"},{"key":"10.2515\/therapie:2004021_bb2230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0893-133X(96)00218-7","article-title":"A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects","volume":"16","author":"Nyberg","year":"1997","journal-title":"Neuropsychopharmacology"},{"issue":"Suppl. 3","key":"10.2515\/therapie:2004021_bb2235","first-page":"81","article-title":"Positron emission tomography studies on D2 dopamine receptor occupancy and plasma antipsychotic drug levels in man","volume":"10","author":"Nyberg","year":"1995","journal-title":"Int Clin Psychopharmacol"},{"issue":"Suppl. 10","key":"10.2515\/therapie:2004021_bb2240","first-page":"15","article-title":"D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET","volume":"60","author":"Remington","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"10.2515\/therapie:2004021_bb2245","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1176\/ajp.156.2.294","article-title":"Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects and neuroendocrine response","volume":"156","author":"Breier","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.2515\/therapie:2004021_bb2250","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4088\/JCP.v59n0205","article-title":"The prevalence of acute extrapyramidal symptoms in patients treated with clozapine, risperidone and conventional antipsychotics","volume":"59","author":"Miller","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"10.2515\/therapie:2004021_bb2255","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/00004714-200006000-00017","article-title":"Adverse effects of high-dose olanzapine in treatment-refractory schizophrenia","volume":"20","author":"Bronson","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"10.2515\/therapie:2004021_bb2260","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1176\/ajp.155.11.1626h","article-title":"Olanzapine overdose cause of acute extrapyramidal symptoms","volume":"155","author":"Chambers","year":"1998","journal-title":"Am J Psychiatry"},{"key":"10.2515\/therapie:2004021_bb2265","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S0924-9338(99)00153-4","article-title":"Deterioration of parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine","volume":"14","author":"Rudolf","year":"1999","journal-title":"Eur Psychiatry"},{"key":"10.2515\/therapie:2004021_bb2270","first-page":"2135","article-title":"Neuroleptiques: principes et r\u00e8gles d\u2019utilisation","volume":"49","author":"Abadie","year":"1999","journal-title":"Rev Prat"},{"issue":"1","key":"10.2515\/therapie:2004021_bb2275","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1590\/S0004-282X2001000100026","article-title":"Worsening of Parkinsonism after the use of veralipride for treatment of menopause: case report","volume":"59","author":"Teive","year":"2001","journal-title":"Arq Neuropsiquiatr"},{"key":"10.2515\/therapie:2004021_bb2280","first-page":"63","article-title":"Evaluation de l\u2019impact d\u2019une lettre d\u2019information sur le m\u00e9toclopramide","volume":"54","author":"Jean-Pastor","year":"1999","journal-title":"Th\u00e9rapie"},{"issue":"1","key":"10.2515\/therapie:2004021_bb2285","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/mds.870120119","article-title":"A long-term follow-up study of cinnarizine- and flunarizine-induced parkinsonism","volume":"12","author":"Negrotti","year":"1997","journal-title":"Mov Disord"},{"key":"10.2515\/therapie:2004021_bb2290","first-page":"1335","article-title":"Syndrome parkinsonien, effet ind\u00e9sirable possible des inhibiteurs calciques","volume":"85","author":"Malaterre","year":"1992","journal-title":"Arch Mal C\u0153ur Vaiss"},{"key":"10.2515\/therapie:2004021_bb2295","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/mds.870100120","article-title":"Parkinsonism induced by amlodipine","volume":"10","author":"Sempere","year":"1995","journal-title":"Mov Disord"},{"key":"10.2515\/therapie:2004021_bb2300","first-page":"57","article-title":"Syndrome parkinsonien sous diltiazem","volume":"56","author":"Remblier","year":"2001","journal-title":"Th\u00e9rapie"},{"key":"10.2515\/therapie:2004021_bb2305","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/mds.10185","article-title":"Parkinsonian syndrome induced by amlodipine: case report","volume":"17","author":"Teive","year":"2002","journal-title":"Mov Disord"},{"key":"10.2515\/therapie:2004021_bb2310","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/mds.870100325","article-title":"Does fluoxetine aggravate Parkinson\u2019s disease?: a pilot prospective study","volume":"10","author":"Montastruc","year":"1995","journal-title":"Mov Disord"},{"key":"10.2515\/therapie:2004021_bb2315","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0278-5846(98)00036-0","article-title":"Extrapyramidal adverse effects associated with sertraline","volume":"22","author":"Lambert","year":"1998","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.2515\/therapie:2004021_bb2320","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00004714-199310000-00016","article-title":"Dyskinesia associated with fluvoxamine","volume":"13","author":"Arya","year":"1993","journal-title":"J Clin Psychopharmacol"},{"key":"10.2515\/therapie:2004021_bb2325","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1192\/bjp.165.6.728","article-title":"Extrapyramidal symptoms with selective serotonin reuptake inhibitors","volume":"165","author":"Arya","year":"1994","journal-title":"Br J Psychiatry"},{"key":"10.2515\/therapie:2004021_bb2330","first-page":"339","article-title":"Fluoxetine-induced akathisia: clinical and theorical implications","volume":"50","author":"Lipinski","year":"1989","journal-title":"J Clin Psychiatry"},{"key":"10.2515\/therapie:2004021_bb2335","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1177\/106002809703101208","article-title":"Extrapyramidal reactions and the selective serotonin-reuptake inhibitors","volume":"31","author":"Caley","year":"1997","journal-title":"Ann Pharmacother"},{"key":"10.2515\/therapie:2004021_bb2340","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/1531-8257(199909)14:5<874::AID-MDS1028>3.0.CO;2-Q","article-title":"SSRI-induced reversal of levodopa benefit in two patients with dopa-responsive dystonia","volume":"14","author":"Mathen","year":"1999","journal-title":"Mov Disord"},{"key":"10.2515\/therapie:2004021_bb2345","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0924-977X(97)00405-7","article-title":"Tricyclic antidepressant-induced extrapyramidal side effects","volume":"7","author":"Vandel","year":"1997","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.2515\/therapie:2004021_bb2350","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1176\/ajp.141.2.283","article-title":"A case of akinesia induced by amoxapine","volume":"141","author":"Gammon","year":"1984","journal-title":"Am J Psychiatry"},{"issue":"3","key":"10.2515\/therapie:2004021_bb2355","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/00002826-200305000-00007","article-title":"Risk of serious extrapyramidal symptoms in patients with Parkinson\u2019s disease receiving antidepressant drugs: a pharmacoepidemiologic study comparing serotonin reuptake inhibitors and other antidepressant drugs","volume":"26","author":"Gony","year":"2003","journal-title":"Clin Neuropharmacol"},{"key":"10.2515\/therapie:2004021_bb2360","first-page":"342","article-title":"Lithium-induced accentuation of extrapyramidal symptoms in individuals with Alzheimer\u2019s disease","volume":"45","author":"Kelwala","year":"1984","journal-title":"J Clin Psychiatry"},{"key":"10.2515\/therapie:2004021_bb2365","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1136\/bmj.2.6036.642-a","article-title":"Extrapyramidal side effects of lithium treatment [letter]","volume":"2","author":"Johnels","year":"1976","journal-title":"BMJ"},{"key":"10.2515\/therapie:2004021_bb2370","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1212\/WNL.47.3.626","article-title":"Reversible parkinsonism and cognitive impairment with chronic valproate use","volume":"47","author":"Armon","year":"1996","journal-title":"Neurology"},{"key":"10.2515\/therapie:2004021_bb2375","first-page":"629","article-title":"D\u00e9mence et troubles extrapyramidaux sous acide valpro\u00efque au long cours","volume":"55","author":"Masmoudi","year":"2000","journal-title":"Th\u00e9rapie"},{"issue":"1","key":"10.2515\/therapie:2004021_bb2380","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4088\/JCP.v63n0114a","article-title":"Valproate-induced parkinsonism in a demented elderly patient","volume":"63","author":"Iijima","year":"2002","journal-title":"J Clin Psychiatry"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716301664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716301664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:25:11Z","timestamp":1683764711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716301664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["S0040595716301664"],"URL":"https:\/\/doi.org\/10.2515\/therapie:2004021","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2004,1]]}}}